V-plex sars-COV-2 key variant spike panel 1 (IGG) kits
Closed Special Notice Posted
- Solicitation number
- NOI-NIAID-24-2204666
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- Place of performance
- Gaithersburg, Maryland 20878, United States
Notice details come from SAM.gov. Updated .
About this opportunity
This Special Notice from the National Institutes of Health announces the agency's intent to negotiate on an other than full and open competition basis with Meso Scale Diagnostic, LLC for the procurement of V-PLEX SARS-CoV-2 Key Variant Spike Panel 1 (IgG) Kits. The National Institute of Allergy and Infectious Diseases requires these kits for high throughput simultaneous measurement of antibodies to spike protein epitopes.
The Special Notice provides details that the V-PLEX kits are needed for COVID-19 vaccine trials, correlate of protection testing, and monoclonal antibody screening. It establishes a deadline of February 22, 2024 for any capable contractors to submit capability statements for consideration, citing 41 U.S.C. 1901(a)(1) and FAR 13.106-1 as allowing for this sole source procurement given Meso Scale Diagnostic's exclusive intellectual property rights. Contractors must email capability statements to Maliaka Pinkney by 12:00pm EST on February 22nd to be reviewed, though award remains at the agency's discretion. This Special Notice is not itself a solicitation but only an advance notice of a planned noncompetitive contract award.
Notice text
This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with Meso Scale Diagnostic, LLC located at 1601 Research Boulevard, Rockville, MD 20850 for (2) V-PLEX SARS-CoV-2 Key Variant Spike Panel 1 (IgG) Kits.
The National Institute of Allergy and Infectious Diseases (NIAID), requires the V-PLEX SARS
CoV-2 Key Variant Spike Panel 1 (IgG) for high throughput for the simultaneous measurement of
antibodies to their epitopes. Spike proteins are 'printed' or 'spotted' in a single well of a MSD 96-
well microtiter plate. The VRC-VIP identified the ECL assay as the most reliable and sensitive
assay system over the last 10 years, that offers high dynamic range in the detection of specific
serum antibodies generate towards a variety of viral proteins. MSD are the sole owners of the intellectual property of the ECL assay designed in collaboration with VIP specifically for VIP endpoint testing for COVID-19 Phase 1-3 trials, correlate of protection testing and screening of SARS CoV-2 mAbs.
The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI-NIAID-24-2204666 to Maliaka Pinkney at maliaka.pinkney@nih.gov, by 12:00 pm eastern standard time February 22, 2024. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.
Similar open opportunities
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity